Products
Isatuximab was approved in many countries, in the EU, and in the United States in 2020 as a concentrate for the preparation of an infusion solution (Sarclisa).
Structure and properties
Isatuximab is a chimeric monoclonal antibody derived from IgG1. It is produced by biotechnological methods. The molecular mass is approximately 148 kDa.
Effects
Isatuximab has antitumor and selective cytotoxic properties. The effects are due to binding to the extracellular epitope of the CD38 receptor, resulting in tumor cell death. CD38 is expressed on the cell surface in multiple myeloma. The half-life is 28 days.
Indications
For the treatment of relapsed and refractory multiple myeloma in adults.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include:
- Neutropenia
- Infusion-related reactions
- Upper respiratory tract infections, pneumonia.
- Fatigue
- Diarrhea, constipation
